Brought to you by 
Dicerna brings in $29mm through its Series B venture round
31 Jan 2014
Executive Summary
Dicerna Pharmaceuticals Inc. (RNA interference therapeutics) has raised $25mm through its Series B venture round. New backer Domain Associates led (and contributes a board member) and was joined by current shareholders Oxford Bioscience Partners, Skyline Ventures, and Abingworth. Dicerna will use some of the proceeds to develop conjugated drug delivery systems, move its lead cancer program into the clinic, and work on its other preclinical drug candidates.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dicerna brings in $29mm through its Series B venture round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice